| Univariable | Multivariable | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | aHR | 95% CI | p-value | |
Age > 60 yr | 0.73 | 0.53–1.00 | 0.049 |  |  |  |
Male | 0.75 | 0.47–1.18 | 0.213 |  |  |  |
PIVKA II > 250 mAU/mL | 1.29 | 0.93–1.80 | 0.133 |  |  |  |
AFP > 200 ng/mL | 1.96 | 1.42–2.72 |  < 0.001 | 1.98 | 1.42–2.75 |  < 0.001 |
Total bilirubin | 1.02 | 0.92–1.14 | 0.663 |  |  |  |
Albumin | 1.18 | 0.888–1.59 | 0.264 |  |  |  |
ALT | 1.00 | 1.00–1.00 | 0.668 |  |  |  |
AST | 1.00 | 1.00–1.00 | 0.236 |  |  |  |
PT | 1.48 | 0.88–2.47 | 0.139 |  |  |  |
Presence of ascites | 0.97 | 0.66–1.42 | 0.867 |  |  |  |
ECOG 1 (vs 0) | 1.53 | 1.07–2.17 | 0.019 |  |  |  |
Child B,C (vs A) | 0.89 | 0.60–1.32 | 0.558 |  |  |  |
BCLC stage C,D (vs B) | 1.43 | 0.83–2.48 | 0.200 |  |  |  |
Tumor size | 1.00 | 1.00–1.00 | 0.828 |  |  |  |
Extrahepatic metastasis | 1.17 | 0.83–1.65 | 0.373 |  |  |  |
Portal vein thrombosis | 1.05 | 0.76–1.44 | 0.787 |  |  |  |
Biliary invasion | 1.20 | 0.63–2.28 | 0.576 |  |  |  |
Lenvatinib (vs sorafenib) | 0.55 | 0.37–0.84 | 0.005 | 0.55 | 0.36–0.84 | 0.005 |
Previous anti-HCC treatment | 0.99 | 0.63–1.57 | 0.966 |  |  |  |